

Diagnostic Challenges and Therapeutic Advances in Paratesticular Rhabdomyosarcoma

Sarah ZEROUAL¹, Sarah TABOURI², Blaha LARBAOUI¹

¹Department of Medical Oncology, Center for the fight against cancer of Oran. "Emir Abd El Kader"- Faculty of Medicine of Oran - Ahmed Ben Bella University – Oran- Algeria.

²Department of Medical Oncology, Center for the fight against cancer of Sidi Bel Abbas. " Taleb Morad" Faculty of Medicine – Djillali Liabes University – Sidi Bel Abbas - Algeria.

*Corresponding Author: Dr. Sarah TABOURI, Department of Medical Oncology, Center for the fight against cancer of Sidi Bel Abbas." Taleb Morad" Faculty of Medicine – Djillali Liabes University – Sidi Bel Abbas - Algeria.

ABSTRACT

Paratesticular rhabdomyosarcoma is a rare and highly aggressive tumor that primarily affects the urogenital system. Despite being relatively uncommon, this disease presents significant challenges due to its aggressive nature. The embryonal subtype is the most frequently encountered. Treatment often requires a multimodality approach, combining surgery, chemotherapy, and radiation therapy, to improve patient outcomes. We report an observation of a paratesticular rhabdomyosarcoma in a 16-year-old patient. We discuss diagnostic and therapeutic modalities based on data from the literature.

Keywords: Paratesticular, Rhabdomyosarcoma, Embryonal Variant, Treatment.

ARTICLE INFORMATION

Received: 07 December 2024

Accepted: 18 December 2024

Published: 19 December 2024

Cite this article as:

Sarah ZEROUAL, Sarah TABOURI, Blaha LARBAOUI. Diagnostic Challenges and Therapeutic Advances in Paratesticular Rhabdomyosarcoma. Journal of Medical Images and Case Reports. 2024;2(1); 07-10.

Copyright: © 2024. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



INTRODUCTION

Paratesticular rhabdomyosarcoma (RMS) is a rare and aggressive malignant mesenchymal tumor originating from connective tissues[1]. The urogenital tract is the most common site of involvement. Paratesticular localization accounts for approximately 7% to 10% of all RMS cases [1-3]. The disease typically presents in two age peaks: early childhood (2-5 years) and adolescence [4]. The embryonal variant is the most common histological subtype and carries a poor prognosis. Clinical presentation is nonspecific, and the diagnosis is confirmed by histopathological examination of the orchiectomy specimen. Management is multidisciplinary, combining surgery, chemotherapy, and radiotherapy, with treatment plans tailored to the clinical stage and prognostic group [5]. We report a case of embryonal paratesticular rhabdomyosarcoma (P-RMS) in a young patient and discuss the clinical and therapeutic aspects of this disease in our context, supported by a literature review.

CASE REPORT

A 16-year-old boy with no significant medical history presented with a one-month history of right scrotal enlargement. Physical examination revealed a firm, painless, and enlarged right testis without associated signs of inflammation. Initial scrotal ultrasound demonstrated multiple solid masses infiltrating the tunica vaginalis (Figure1).

Tumor markers, including alpha-fetoprotein, lactate dehydrogenase (LDH), and human chorionic gonadotropin (hCG), were within normal limits. An inguinal orchiectomy with high ligation of the spermatic cord was performed. Histopathological examination with immunohistochemistry revealed an embryonal rhabdomyosarcoma with spindle cells infiltrating the epididymis and base of the cord, with positive staining for actin, desmin, and myogenin (Figure02).




Figure 1. *Ultrasound aspect of the testicle showing multiple solid scrotal tumor formations infiltrating the vaginal tunics (Photo credit Dr Sarah ZEROUAL)*




Figure 2 . *Histopathological aspect of the tumor process on hématoxyline-éosine stain (Presence of spindle-shaped tumor cells. Photo credit: Dr Sarah ZEROUAL).*

A computed tomography (CT) scan of the chest, abdomen, and pelvis, performed for staging, revealed bilateral pulmonary nodules, as well as intra-abdominal and inguinal lymph node involvement. The tumor was staged as IV according to the Intergroup Rhabdomyosarcoma Study (IRS) classification.

The patient was initiated on a multi-agent chemotherapy regimen (IVA protocol) consisting of ifosfamide, vincristine, and actinomycin D. A follow-up CT scan after the third cycle of chemotherapy demonstrated a partial response of the pulmonary and nodal lesions. However, a subsequent CT scan after three additional cycles showed progressive disease with an increase in the size and number of pulmonary nodules, along with the development of cough and dyspnea. A salvage chemotherapy regimen with cyclophosphamide and etoposide was initiated. Unfortunately, the patient developed Fournier's gangrene and succumbed during emergency surgery.

DISCUSSION

Paratesticular rhabdomyosarcoma (PT-RMS) represents 7-10% of all RMS tumors arising in the genitourinary tract, making it the third most common site after the prostate and bladder. The disease exhibits a bimodal age distribution, with peaks occurring in early childhood (1-5 years) and adolescence (16 years) [1-6].

The most frequent presenting symptom of PT-RMS is a scrotal mass, accounting for 85% of cases, consistent with the typical presentation described in the literature [7-8]. Other less common presenting symptoms include trauma or bruising (8%) and hydrocele or hernia (6%). Physical examination often reveals a palpable mass, although a hydrocele may mask the underlying testicular tumor in 15-20% of cases. Differential diagnoses to consider include testicular torsion, hydrocele, epididymo-orchitis, inguinal hernia, and mumps orchitis. However, the paratesticular nature of these tumors can be challenging to determine on physical examination alone. The rapid, often painless growth of PT-RMS contributes to early local invasion and a high risk of distant metastasis [9]. Metastatic spread most commonly involves the retroperitoneal lymph nodes, lungs, liver, and bones [9]. Unfortunately, there are no specific tumor markers to aid in the diagnosis of PT-RMS. The definitive diagnosis relies on the histopathological examination of the tissue obtained from an inguinal orchiectomy [10].

Histologically, three types of rhabdomyosarcoma exist: embryonal, the most common (97% of cases) with a poor prognosis due to frequent nodal involvement at diagnosis, as seen in our patient who presented with pulmonary and nodal metastases at initial evaluation; alveolar, and pleomorphic [11-15].

- **Embryonal RMS:** The most common subtype, accounting for approximately 80% of cases. It is characterized by its expression of skeletal muscle markers and is thought to arise from muscle progenitor cells or through trans-differentiation of mesenchymal tissue (Figure 3). Histological examination remains the gold standard for diagnosis and classification. While gene fusions, particularly PAX7/FOXO1 and PAX3/FOXO1, have been used for risk stratification, their prognostic significance is still being investigated. The International Classification of Rhabdomyosarcoma (ICR) has refined the classification system, leading to a more accurate assessment of tumor behavior and prognosis[15-16].
- **Alveolar RMS:** Associated with a worse prognosis, especially those with PAX7 or PAX3 gene fusions. However, a significant proportion of alveolar RMS cases lack these fusions.
- **Spindle Cell and Sclerosing RMS:** Rare subtypes with overlapping histological features .




Figure 3. Histopathological appearance of Embryonal Rhabdomyosarcoma.

A.Low power image showing cellular neoplasm with hyper and hypocellular areas. (H&E, 200x) B. High power image showing primitive spindle cells with scattered rhabdomyoblasts. (H&E, 400x).

Discovery of a scrotal mass will be complemented by a systematic testicular ultrasound. It shows a mass with a heterogeneous echotexture, with inguinoscrotal extension in 80% of cases [17]. Echo-Doppler reveals a hypervascular appearance of the tumor mass and specifies its extratesticular location [17]. Conventional CT scan has been used for evaluation of the retroperitoneum and current recommendations are that all patient sunder go thin cut(5mm for age<10 years, 7mm for age > 10 years) abdominal or pelvic CT with double contrast to identify regional retroperitoneal lymph node involvement for staging purposes [18-19].

The locoregional extension assessment can be completed by an MRI. MRI is a high-performance imaging modality, using surface coils; the tumor appears homogeneous on T1-weighted images and heterogeneous on T2-weighted images with a signal intensity similar to the normal testis. Due to the hypointensity of the tunica albuginea on T2-weighted images, the mass is clearly separated from the testis [16-17]. For the assessment of distant metastases, a thoraco-abdominopelvic computed tomography (CT) scan allows the detection of deep lymph node involvement,

especially the lumbar-aortic and pelvic nodes, as well as hepatic and pulmonary metastases. The assessment of distant metastases also includes a bone scan [9,18].

18F-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/CT has been studied as a more sensitive tool in staging and restaging of patients with RMS. Tateishi and colleagues compared the sensitivity of FDG PET/CT to that from conventional imaging(CI) (whole body CT, bone scan, and MRI) of the primary site. They demonstrated that using PET/CT, M stage was correctly assigned in 89% of patients compared with 63% when CI was used. There was also improved accuracy with nodal metastases being identified in 86% of patients undergoing PET/CT compared with 54% undergoing CI [20].

The classification of RMS malignancies is unique and can be confusing due to the 2 different prognostic systems used by the IRSG during their clinical trials. Risk stratification relies on both a pretreatment (Tumor-node-metastasis [TNM]) staging system and a surgical or pathologic clinical grouping system based on the extent of disease following initial surgery [18]. Therefore, during IRS-I/II, patients were separated into prognostic categories, referred to as “groups,” based on the extent of disease remaining after primary surgical intervention. (Table 1).

Table 1. TNM Pretreatment Staging System (IRSG) [18]

I	Localized disease, completely resected	
	A	Confined to the organ or muscle or origin
	B	Infiltration outside organ or muscle or origin; regional nodes not involved
II	Total gross resection with evidence of regional spread	
	A	Grossly resected tumors with “microscopic” residual tumor
	B	Regional disease completely resected with regional nodes involved, tumor extension into adjacent organs, or both.
III	Incomplete resection or biopsy with gross residual disease remaining	
	A	Localized or locally extensive tumor, gross residual disease after biopsy only
	B	Localized or locally extensive tumor, gross residual disease after “major” resection (>50% debulking)
IV	Any size primary tumor, with or without regional lymph node involvement, with distant metastases irrespective of surgical approach to the primary tumor	

With the advent of multimodal therapy, a pretreatment TNM staging system was introduced for IRS-III. This system considers tumor size, invasiveness, nodal status, and distant metastases. Additionally, tumor location (favorable or unfavorable) was identified as a significant prognostic factor (Table 2).

The IRS-IV study combined stage, group, and histological subtype to classify patients into low, intermediate, and high-

risk categories, guiding treatment decisions (Table3).

PT-RMS can be either stage I or IV given its location as a favorable primary site. Risk stratification was introduced during IRS-V, in which the study combined stage, group, and histological subtype to place patients into different therapeutic protocols according to risk of recurrence (Table 4)

Table 2. Clinical grouping for patients with rhabdomyosarcoma [18]

Classification Description	
Tumor	
T1	Confined to anatomical site of origin
a	<5 cm in diameter
b	≥5 cm in diameter
T2	Extension or fixation to surrounding tissue
a	<5 cm in diameter
b	≥5 cm in diameter
Regional lymph nodes	
N0	Regional lymph nodes not clinically involved
N1	Regional lymph nodes clinically involved by neoplasm
Nx	Clinical status of regional lymph nodes unknown (especially with sites that preclude lymph node evaluation)
Metastasis	
M0	No distant metastasis
M1	Metastasis present

Table 3. Soft Tissue Sarcoma Committee of the Children’s Oncology Group: pretreatment staging system [18]

Stage	Sites	T	Tumors Size	N	M
Favorable					
I	Orbit	T1 or T2	a or b	N0 or N1 or N2	M0
	Head and neck (excluding parameningeal)				
	GU-non bladder or non prostate				
II	Bladder or prostate	T1 or T2	b	N0 or Nx	M0
	Extremity				
	Head and neck parameningeal				
	Other (including trunk, retroperitoneum, etc.)				
Unfavorable					
III	Bladder or prostate	T1 or T2	a b	N1 N0 or N1 or Nx	M0
	Extremity				
	Head and neck parameningeal				
	Other (including trunk, retroperitoneum, etc.)				
Metastasis					
IV	All	T1 or T2	a or b	N0 or N1	M1

The 3 year failure free survival (FFS) rate was 88% for low risk patients, 55-76% for intermediate risk patients, and less than 30% for high-risk patients [19].

In Summary RMS staging involves three key factors:

1. Stage: Based on pretreatment characteristics, including tumor location, size, nodal involvement, and distant metastases.

2. Group: Determined post-surgery by assessing residual disease and lymph node status.

3. Risk Category: A combination of stage, group, and histological subtype used for risk stratification and treatment planning.

Table 4. *Soft Tissue Sarcoma Committee of the Children’s Oncology Group: rhabdomyosarcoma risk group classification [18]*

Risk group	Histology	Stage	Group
Low risk	Embryonal	1	I, II, III
	Embryonal	2, 3	I, II
	Embryonal	2, 3	III
Intermediate risk	Alveolar	1, 2, 3	I, II, III
High risk	Embryonal or alveolar	4	IV

Multimodal treatment with systemic chemotherapy in conjunction with either surgery, RT, or both is used to maximize tumor control. Before using effective chemotherapy agents, surgical intervention alone produced approximately a 50% 2-year relapse-free survival [19,21]. Treatment guidelines for the surgical management of PT-RMS, including primary inguinal orchidectomy, pretreatment re-excision (PRE), management of large tumors, trans-scrotal excision, scrotal violation, hemi-scrotectomy (HS), testicular transposition and retroperitoneal lymph node assessment and management [22].

Use of retroperitoneal lymph node dissection (RPLND) of RPLND in PT-RMS is controversial and has evolved over the past 20 years. Approximately 25% of patients with PT-RMS are found to have retroperitoneal lymph node disease at presentation [18]. Historically, RPLND was recommended for all patients with localized renal tumors, but recent studies have shown that this approach may lead to overtreatment in certain cases.

Adolescent male patients and those with primary tumors exceeding 7 cm are at heightened risk of retroperitoneal lymph node (RPLN) metastasis [19]. Current treatment guidelines advocate for RPLND in all adolescent boys and younger boys with suspicious lymph nodes on CT scans [22-24]. Additionally, RPLND is indicated for patients with confirmed RPLN metastasis, except in cases of excessively large lymph nodes. For low-risk patients with concerning imaging findings, PET/CT scans can aid in identifying true metastatic disease, thereby preventing unnecessary surgery [25]. While RPLND is a valuable tool, it carries potential risks, including bowel obstruction, retrograde ejaculation, and lymphedema. Therefore, treatment decisions should be tailored to individual patient characteristics, imaging findings, and risk assessment. Ongoing research endeavors to refine treatment strategies to optimize outcomes while minimizing adverse effects [25-28].

The primary objectives of chemotherapy in this context are to enhance overall survival and diminish the likelihood of disease recurrence. Multiple chemotherapy regimens have been investigated, including VAC, IVA, and VIE (consisting of vincristine, actinomycin D, etoposide or ifosfamide, and cyclophosphamide) [29]. Among these, the VAC regimen is the most widely adopted. In cases of tumor resistance or progression, additional agents such as doxorubicin, cisplatin, and bleomycin may be incorporated into the treatment plan [30].

Treatment with alkylating agents like cyclophosphamide and ifosfamide has been shown to affect fertility by depletion of the germinal epithelium. It has been shown that depletion of the germ cell epithelium is dose dependent [31].

Complete surgical resection as primary or salvage treatment is not always feasible and radiation therapy (RT) has assumed a major role in the management of RMS [18]. In contrast with other primary sites, up to 82% of PT-RMS are diagnosed in a localized stage and able to be completely resected [14,32].

RT has been primarily used as a salvage treatment for nodal extension or in cases of incomplete surgical resection [32]. Its role in treating locally advanced or nodal disease remains controversial. While the Children’s Oncology Group (COG) recommends RT for patients with group II-III disease, the Société Internationale d’Oncologie Pédiatrique (SIOP) reserves RT for patients with poor response to systemic therapy or incomplete resection [33-34]. Both groups, however, have achieved similar 5-year overall survival (OS) and failure-free survival (FFS) rates. This suggests that the necessity of RT following RPLND in patients with pathologically confirmed nodal disease may be questionable [35].

For patients with advanced stage disease in the retroperitoneum, the extent of RT depends on the

completeness of post-chemotherapy RPLND. Patients with complete resection receive a lower dose of RT (41.4 Gy) compared to those with incomplete resection (50.4 Gy) [36].

While RT has shown benefit in improving FFS for patients with alveolar histology, it does not appear to provide additional benefit for patients with embryonal variants or other poor prognostic factors [18].

Although radiation therapy (RT) has significantly improved survival rates for pediatric renal cell tumors, it is associated with substantial long-term side effects. A retrospective study by Hughes et al. highlighted the potential risks, including fatal complications, organ damage, and growth impairment [37]. Despite these challenges, advancements in RT techniques, such as intensity-modulated radiation therapy (IMRT) and proton beam therapy, offer promise in reducing toxicity while maintaining therapeutic efficacy. These technologies allow for precise dose delivery to the tumor while minimizing exposure to surrounding healthy tissues.

CONCLUSION

Paratesticular rhabdomyosarcoma, while a rare malignancy, presents as an urgent diagnostic and therapeutic challenge, particularly in children and young adults. Early diagnosis, accurate staging, and a standardized treatment regimen involving surgery, multi-agent chemotherapy, and radiotherapy have significantly improved outcomes. Long-term follow-up is essential to detect potential recurrences. The introduction of multi-agent chemotherapy has dramatically transformed the prognosis for patients with paratesticular rhabdomyosarcoma, with 3-year overall survival rates reaching 95%. Ongoing advancements in genomic testing and imaging technologies offer promising opportunities to further personalize treatment strategies, optimizing both cancer control and minimizing long-term side effects.

REFERENCES

1. Asensio LA, Abaitua Bilbao J. Paratesticular rhabdomyosarcoma. Diagnostic and therapeutic indications. *J Urol (Paris)*. 1993;99(1):44-6.
2. Blyth B and al. Paratesticular rhabdomyosarcoma: results of therapy in 18 cases. *J Urol*. 1990 Dec;144(6): 1450-3.
3. Durand X and al. Recommandations en onco-urologie 2013 : tumeurs germinales du testicule. *Prog Urol*. 2013 Nov;23 Suppl 2: S145-160.
4. Wu HY, Snyder HM 3rd, Womer RB. Genitourinary rhabdomyosarcoma: which treatment, how much, and when?. *J Pediatr Urol*. 2009 Dec;5(6): 501-6.
5. American cancer society: "How is rhabdomyosarcoma staged?" in. Google Scholar

6. Faure A, Diakité ML, Panait N, Chaumoître K, Rome A, Merrot T. Paratesticular rhabdomyosarcoma in children: a scrotal emergency. *Arch Pediatr*. 2012 Dec;19(12): 1340-4.
7. Zheng L, Tang H, Chen X, Yang H, Yang M. Paratesticular fetal-type rhabdomyoma in a 12-year-old boy: a case report and literature review. *Urology*. 2013 Nov;82(5): 1150-2.
8. Dasgupta R, Rodeberg DA. Update on rhabdomyosarcoma. *Semin Pediatr Surg*. 2012 Feb;21(1): 68-78.
9. Slama A, Jaidane M, Ben Sorba N, Youssef A, Misbah Ali FM. Le rhabdomyosarcome paratesticulaire. *Prog Urol*. 2000 Dec;10(6): 1232-4
10. Dasgupta R, Rodeberg DA. Update on rhabdomyosarcoma. *Semin Pediatr Surg*. 2012 Feb;21(1): 68-78.
11. Yasui N, Yoshida A, Kawamoto H, et al. Clinicopathologic analysis of spindle cell/sclerosing rhabdomyosarcoma. *Pediatr Blood Cancer* 2015;62:1011–6.
12. Fletcher CDM, Bridge JA, Hogendoorn PCW, et al. WHO classification of tumours of soft tissue and bone. Lyon, France: IARC Press, 2013;134–5.
13. Ferrari A, Bisogno M, Casanova C, et al. Paratesticular Rhabdomyosarcoma: report from the Italian and German Cooperative Group. *J Clin Oncol* 2002;20:449–55.
14. Hatley ME, Tang W, Garcia MR, et al. A mouse model of rhabdomyosarcoma originating from the adipocyte lineage. *Cancer Cell* 2012;22:536–46.
15. Narasimhan P, Agaram, M.B.B.S. Evolving Classification of Rhabdomyosarcoma. *Histopathology*. 2022 January ; 80(1): 98–108.
16. Stephenson A and al. Diagnosis and treatment of early stage testicular cancer: AUA Guideline. *J Urol*. 2019 Aug; 202(2): 272-281.
17. Pankaj P and al. Current management of paratesticular rhabdomyosarcoma. *Urologic Oncology: Seminars and Original Investigations* (2015) 1–9
18. Crist WM and al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. *J Clin Oncol* 2001;19:3091–102.
19. Tateishi U and al. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. *Ann Nucl Med* 2009;23:155–61.
20. Cecchetto G and al. Surgical compliance with guidelines for paratesticular rhabdomyosarcoma (RMS). Data from the European Study on non-metastatic RMS. *J Pediatr Surg* 2012; 47:2161–2.
21. Timothy N. and al. Surgical Management of Paratesticular Rhabdomyosarcoma: A Consensus Opinion from the Children’s Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. *Pediatr Blood Cancer*.

- 2022 April ; 68(4): e28938. doi:10.1002/abc.28938.
22. Crist W and al. The Third Intergroup Rhabdomyosarcoma Study. *J Clin Oncol* 1995;13:610–30.
 23. Alanees S, and al. Primary tumor size predicts pathologic findings in the retroperitoneal lymph nodes in patients with paratesticular rhabdomyosarcoma. *Virchows Arch* 2014;465:697–701.
 24. Goldfarb B, and al. The role of retroperitoneal lymphadenectomy in localized paratesticular rhabdomyosarcoma. *J Urol* 1994;152:785–7.
 25. Ferrari A and al. The management of paratesticular rhabdomyosarcoma: a single institutional experience with 44 consecutive children. *J Urol* 1998;159:1031–4.
 26. Heyn R and al. Late effects of therapy in patients with paratesticular rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Committee. *J Clin Oncol* 1992;10:614–23.
 27. Baniel J and al. Complications of primary retroperitoneal lymphnode dissection. *J Urol* 1994;152:424–7.
 28. Ferrari A, Casanova M, Massimo M, Luksch R, Piva L, Fossati-Bellani F. The management of paratesticular rhabdomyosarcoma a single institutional experience with 44 consecutive children. *J Urol*. 1998 Mar;159(3): 1031-4.
 29. Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL *et al*. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the international society of paediatric oncology-SIOP malignant mesenchymal tumor 89. *J Clin Oncol*. 2005 Apr 20;23(12): 2618-28.
 30. Sklar CA, La Quaglia MP. The long-term complications of chemotherapy in childhood genitourinary tumors. *Urol Clin North Am* 2000; 27:563–8.
 31. Stewart RJ and al. International Society of Pediatric Oncology. Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT84 and MMT89) of the International Society of Pediatric Oncology. *J Clin Oncol* 2003;21:793–8.
 32. Wu HY, Snyder HM, Womer RB. Genitourinary rhabdomyosarcoma: which treatment, how much, and when? *J Pediatr Urol* 2009;5:501–6.
 33. Stevens MC and al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Pediatric Oncology—SIOP malignant mesenchymal tumor 89. *J Clin Oncol* 2005;23:2618–28.
 34. Wolden SL and al. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Studies I to III. *J Clin Oncol* 1999;17:3468–75.
 35. Breneman J and al. Local control with reduced dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children’s Oncology Group D9602 study. *Int J Radiat Oncol Biol Phys* 2012;83:720–6.
 36. Hughes LL and al. Paratesticular rhabdomyosarcoma: delayed effects of multimodality therapy and implications for current management. *Cancer* 1994;73:476–82.